[177Lu]-FPI-2263

N/A

Report date: 2025/06/11 11:25:15

NME

Base Information

Drug Name[177Lu]-FPI-2263

Drug Alias Name177Lu-labeled anti-PSMA-FPI-2263 (Fusion Pharma)Lutetium-177-FPI-2263 (Fusion Pharma)177Lu-labeled-FPI-2263 (Fusion Pharma)Lutetium-177-FPI-2263177Lu-FPI-2263 +[6]

ClassificationDiagnostic agent (In vivo)Small moleculesRadiation-emitting products > Radioactive diagnostic agent

Mechanisms of ActionProstate-Specific Membrane Antigen modulators

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanada

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesFusion Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesFusion Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A